Moleculin Biotech, Inc.
MBRX
$2.34
-$0.10-4.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.82% | -0.10% | -4.78% | -9.23% | -12.28% |
| Depreciation & Amortization | -28.57% | -13.85% | -6.87% | -3.85% | -1.56% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.77% | -16.27% | -8.25% | -7.32% | -10.09% |
| Operating Income | 5.77% | 16.27% | 8.25% | 7.32% | 10.09% |
| Income Before Tax | -28.84% | -87.32% | -31.79% | -2.57% | 12.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.84% | -87.32% | -31.79% | -2.57% | 12.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.84% | -87.32% | -31.79% | -2.57% | 12.50% |
| EBIT | 5.77% | 16.27% | 8.25% | 7.32% | 10.09% |
| EBITDA | 5.66% | 16.28% | 8.26% | 7.34% | 10.13% |
| EPS Basic | 73.16% | 68.40% | 61.27% | 47.37% | 45.95% |
| Normalized Basic EPS | 73.18% | 68.40% | 61.27% | 47.37% | 45.95% |
| EPS Diluted | 73.16% | 68.40% | 61.27% | 47.37% | 45.95% |
| Normalized Diluted EPS | 73.18% | 68.40% | 61.27% | 47.37% | 45.95% |
| Average Basic Shares Outstanding | 760.10% | 528.12% | 276.09% | 144.41% | 74.28% |
| Average Diluted Shares Outstanding | 760.10% | 528.12% | 276.09% | 144.41% | 74.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |